Novel Alpha Radiopharmaceutical Therapy Shows Promise in Early-Phase Prostate Cancer Trial

A novel alpha-emitting radiopharmaceutical therapy has demonstrated a favorable safety profile and encouraging signs of antitumor activity in a first-in-human phase I clinical trial involving patients with advanced prostate cancer. The findings, published in The Journal of Nuclear Medicine, highlight the potential of targeting prostate-specific membrane antigen with high-energy alpha particles to address limitations seen in conventional beta-emitting treatments.

Understanding the Limitations of Current Radiotherapies

Prostate-specific membrane antigen-targeted radiopharmaceutical therapy has become an established option for managing metastatic androgen pathway modulation-resistant prostate cancer. Although beta-emitting treatments such as 177Lu-PSMA-617 have successfully improved overall and radiographic progression-free survival in pivotal clinical trials, significant hurdles remain. Approximately one-third of patients do not respond to beta emitters, and the majority of those who initially respond eventually experience disease progression during or shortly after treatment.

Researchers note that conventional radiotherapies often rely on fixed dosing regimens that fail to account for individual variability in tumor response. Furthermore, beta particles release lower-energy radiation that travels up to a couple of millimeters, whereas alpha emitters release high-energy particles that travel only a few cell widths. This mechanism delivers concentrated radiation directly to malignant cells while minimizing exposure to surrounding healthy tissue.

TheraPb Phase I Trial Design and Safety Findings

The TheraPb trial evaluated both escalating doses and varying dosing frequencies of the alpha-targeting radiopharmaceutical therapy known as 212Pb-ADVC001. The first-in-human study enrolled 22 participants with progressive metastatic disease who had previously undergone treatment with an androgen-receptor pathway inhibitor and taxane chemotherapy.

Investigators administered escalating doses ranging from 60 to 200 MBq of 212Pb-ADVC001 at prespecified intervals of every six, four, two, or one week for up to six doses across seven dose-schedule cohorts. The primary evaluations focused on identifying dose-limiting toxicities and adverse events to establish recommended doses for future phase II testing, alongside monitoring prostate-specific antigen responses, radiographic progression-free survival, and overall response rates.

• No dose-limiting toxicities were observed during the trial, and the maximum tolerated dose was not reached.
• The most frequently reported treatment-related adverse events were mild dry mouth and nausea.
• No serious adverse events were documented among the study participants.
• Based on the safety profile, the study committee selected 160 and 200 MBq as the recommended doses for the upcoming phase II trial.

Efficacy and Future Outlook

In addition to favorable tolerability, the early-phase evaluation revealed notable signs of clinical activity. Among the 22 participants, 80% experienced a decline in prostate-specific antigen levels of at least 50%. The median radiographic progression-free survival reached 11.2 months, and the overall response rate was reported at 100%. Study authors emphasize that the flexibility in dosing and the manageable safety profile of 212Pb-ADVC001 provide a strong rationale for investigating combination strategies with other anticancer agents in subsequent clinical research to further improve patient outcomes.